Extending a course of breast cancer medication for a further five years could lower the chances of it returning, according to experts. Results presented at the American found that women with hormone receptor positive breast cancer, which is sensitive to oestrogen, who took aromatase inhibitors (AIs) for 10 years rather than five were more likely to Around 40,000 women in Britain with the most common form of breast cancer could further reduce the risk of it returning or developing in another breast by up to 20 per cent if they stay on medication for an additional decade, new research shows.

Source: The Times June 05, 2016 16:52 UTC